HPP 404

Drug Profile

HPP 404

Alternative Names: HPP404

Latest Information Update: 28 Jul 2015

Price : $50

At a glance

  • Originator Novo Nordisk
  • Developer vTv Therapeutics
  • Class Anorectics; Obesity therapies; Small molecules
  • Mechanism of Action Histamine H3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Diabetes mellitus; Obesity

Most Recent Events

  • 14 Jul 2014 High Point Pharmaceuticals terminates a phase II trial in Obesity in USA (NCT01540864)
  • 29 Aug 2012 High Point Pharmaceuticals completes enrolment in its phase II trial for Obesity in USA (NCT01540864)
  • 09 May 2012 Phase-II clinical trials in Obesity in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top